

PE/iFluor™ 647 Anti-human CD62 Antibody *HI62E*

Catalog number: 106201Q0, 106201Q1, 106201Q2

Unit size: 25 tests, 100 tests, 500 tests

Product Details

Storage Conditions 2-8°C with minimized light exposure. Do not freeze.

Expiration Date 12 months upon receiving

Concentration 0.1 mg/mL

Formulation Phosphate-buffered saline (PBS, pH 7.2), 0.09% sodium azide, 0.2% (w/v) BSA

Antibody Properties

Species Reactivity Human

Class Primary

Clonality Monoclonal

Host Mouse

Isotype Mouse IgG2a

Immunogen CD62e (E-selectin, ELAM-1)

Clone HI62E

Conjugate PE/iFluor™ 647

Biological Properties

Preparation Antibody purified by affinity chromatography and then conjugated with PE/iFluor™ 647 under optimal

conditions

Application Flow Cytometry (FACS)

Spectral Properties

Conjugate PE/iFluor™ 647

Excitation Wavelength 569 nm

Emission Wavelength 666 nm

Applications

The HI62E monoclonal antibody reacts with human CD62e, a 115 kD single-pass type i membrane protein frequently expressed on the surface of endothelial cells and tnf α)s. CD62 has been associated with vital biological processes like inflammatory response, particularly leukocyte migration involved in inflammatory response. Also, in many organisms, it is an enhancer of receptor internalization. From a research standpoint, it is of biological interest due to its association with key macromolecules/ligands such as a and Sialyl Lewis x. CD62 is a relatively rare antibody target, with fewer than FAKE103000FAKE publications in the last decade. Even still, CD62e is often used in flow cytometry applications as a

| phenotypic marker for differentiation of cell types, antibody was purified through affinity chromatogra nm laser and 702/85 nm bandpass filter (for examp | aphy and conjugated to PE/iFluor™ | 647 (ex/em = 569/666 nm). It is com | mmunology. This patible with the 561 |
|---|-----------------------------------|-------------------------------------|--------------------------------------|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |